Literature DB >> 23780896

Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma.

Chen-chen Feng1, Guan-xiong Ding, Ning-hong Song, Xuan Li, Zhong Wu, Hao-wen Jiang, Qiang Ding.   

Abstract

To investigate the correlation between parathyroid hormone-related protein (PTHrP), erythropoietin (EPO), and vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma (ccRCC). Immunohistochemical studies on PTHrP, EPO and VEGF were performed in 249 patients with ccRCC. Serum calcium level and haematocrit were analyzed. The expression of the factors and clinicopathological parameters were studied statistically for possible correlations. The incidence for hypercalcaemia and polycythaemia were 15.3% and 2.0% respectively. Expression of PTHrP, EPO, and VEGF were respectively related to advanced stage (P < 0.0001 respectively). PTHrP was not related to tumour grade. Expressions of EPO and VEGF were correlated to tumour grade significantly. All factors were expressed higher in hypercalcaemic patients. PTHrP, EPO, and VEGF were positively correlated with each other in non-hypercalcaemic patients yet not in hypercalcaemic ones. PTHrP and EPO are related to VEGF expression and to the progression of ccRCC. This finding offers us new insight on the behaviour of ccRCC and offers possible targets in RCC treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23780896     DOI: 10.1007/s13277-013-0924-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

1.  Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma.

Authors:  Kan Gong; Ning Zhang; Zheng Zhang; Yanqun Na
Journal:  Cancer Biol Ther       Date:  2006-06-15       Impact factor: 4.742

2.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Gene expression of erythropoietin in renal cell carcinoma.

Authors:  Y Noguchi; T Goto; Y Yufu; N Uike; Y Hasegawa; T Fukuda; A Jimi; A Funakoshi
Journal:  Intern Med       Date:  1999-12       Impact factor: 1.271

4.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 5.  Renal cell carcinoma.

Authors:  R J Motzer; P Russo; D M Nanus; W J Berg
Journal:  Curr Probl Cancer       Date:  1997 Jul-Aug       Impact factor: 3.187

Review 6.  Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.

Authors:  Brian I Rini; Eric J Small
Journal:  J Clin Oncol       Date:  2004-11-08       Impact factor: 44.544

Review 7.  Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets.

Authors:  T L Clemens; S Cormier; A Eichinger; K Endlich; N Fiaschi-Taesch; E Fischer; P A Friedman; A C Karaplis; T Massfelder; J Rossert; K D Schlüter; C Silve; A F Stewart; K Takane; J J Helwig
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

8.  Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia.

Authors:  Michael S Wiesener; Philine Münchenhagen; Markus Gläser; Bettina A Sobottka; Karl X Knaup; Katrin Jozefowski; Jan Steffen Jürgensen; Jan Roigas; Christina Warnecke; Hermann-Josef Gröne; Patrick H Maxwell; Carsten Willam; Kai-Uwe Eckardt
Journal:  Int J Cancer       Date:  2007-12-01       Impact factor: 7.396

9.  Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis.

Authors:  Hyung L Kim; Arie S Belldegrun; Danielo G Freitas; Matthew H T Bui; Ken-ryu Han; Frederick J Dorey; Robert A Figlin
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  5 in total

1.  TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma.

Authors:  Daniel P Hall; Nicholas G Cost; Shailaja Hegde; Emily Kellner; Olga Mikhaylova; Yiwen Stratton; Birgit Ehmer; William A Abplanalp; Raghav Pandey; Jacek Biesiada; Christian Harteneck; David R Plas; Jarek Meller; Maria F Czyzyk-Krzeska
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

2.  Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

Authors:  Makito Miyake; Steve Goodison; Adrienne Lawton; Ge Zhang; Evan Gomes-Giacoia; Charles J Rosser
Journal:  J Hematol Oncol       Date:  2013-09-03       Impact factor: 17.388

3.  Overexpression of CKAP4 is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma and Functions via Cyclin B Signaling.

Authors:  Chen-Min Sun; Jiang Geng; Yang Yan; Xudong Yao; Min Liu
Journal:  J Cancer       Date:  2017-10-23       Impact factor: 4.207

4.  VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells.

Authors:  Alissa C Greenwald; Tamar Licht; Saran Kumar; Sunday S Oladipupo; Seema Iyer; Myriam Grunewald; Eli Keshet
Journal:  J Exp Med       Date:  2018-12-13       Impact factor: 14.307

5.  Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma.

Authors:  Daniel Beltrame Ferreira; Walter Henriques da Costa; Diego Abreu Clavijo; Ricardo Decia; Isabela Werneck Cunha; Luciana Schultz; Rafael Malagoli Rocha; Gustavo Cardoso Guimarães; Stênio de Cássio Zequi
Journal:  Kidney Cancer       Date:  2017-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.